JAGUAR HEALTH, INC. Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities
JAGUAR HEALTH, INC. (JAGX) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities of 739.55 thousand shares for the 3-month period ending 2017-09-30, per its 10-Q filed 2018-11-19.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities · last filed 2018-11-19
- JAGUAR HEALTH, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2017-09-30 was 739.55K shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 3 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 3 month as first filed |
|---|---|---|
| 2017-09-30 | 739.55K shares 10-Q · filed 2018-11-19 | 11.09M shares 10-Q · filed 2017-11-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |